To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

NCT06948539 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
66
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.